ESPIAL TRIA
- Conditions
- hypertension
- Registration Number
- JPRN-jRCTs051210066
- Lead Sponsor
- Asakura Masanori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 110
(1) Patients aged from 20 to 90 years
(2) Patients diagnosed with hypertension
(3) Patients diagnosed with heart failure
(4) Patients who has UACR of more than 30mg/gCre
(5) Use of ACE-I, ARB, or conpounds containing these
(6) Patients who are capable of providing written consent
(1) Use of MRA for more than 7 days in the past 3 month
(2) Use of Amlodipine at maximum dose
(3) Patients with serum potassium level >5.0mmol/L
(4) Patients are on potassium supplementation
(5) Patients with renal impairment with an eGFR <30 mL/min/1.73m2
(6) Patients with hepatic dysfunction with AST or ALT 3-fold of upper limit of normal
(7) Patients initiated with SGLT2 inhibitor within a month before the consent
(8) Patients who are pregnant, possibly pregnant, or breast feeding
(9) Patients who have been enrolled in other clinical studies at the same time with this study
(10) Patients who are judged by the investigator or subinvestigators to be not suitable for participation in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method